Pharming Group N.V. ("Pharming" or the "Company") (Euronext Amsterdam: PHARM) announces today the placement of €100 million of senior unsecured convertible bonds due 2029 (the “New Bonds”) convertible into new and/or existing ordinary shares in the capital of the Company (the "Shares"). The offer was fully subscribed. The New Bonds were offered via an accelerated book building process through a private placement only to institutional investors outside the United States of America, Australia, Canada, Japan and South Africa.

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.

This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency.

Pharming Group N.V. announces that the Company’s 2024 Annual General Meeting of Shareholders (the “AGM”) will be held on Tuesday, May 21, 2024 at 14:30 CEST.

Pharming Group N.V. announces the filing of its Annual Report for the year ended December 31, 2023 (the “Period”).

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the month of April:

By: Anurag Relan, Pharming Chief Medical Officer

Pharming Group N.V. presents its preliminary (unaudited) financial report for the three months and full year ended December 31, 2023.

A conversation with Sarah, mom to Tyler and Kaitlyn, who are living with a rare disease known as APDS

Pharming Group N.V. confirms it will report its preliminary (unaudited) fourth quarter and full year 2023 financial results, for the period ended December 31, on Thursday, March 14, 2024.